Research And Development

Our research and development efforts have been primarily focused on building a portfolio of proprietary drug candidates based on allosteric modulation, which have broad application across a wide range of biological targets and therapeutic areas. Our primary focus has been on G-protein coupled receptors, or GPCR, targets implicated in neurological diseases, where there is a clear medical need for new therapeutic approaches. Based on this, we have developed a pipeline of proprietary clinical and preclinical stage drug candidates. We or our partners are developing these clinical and preclinical stage proprietary drug candidates for diseases for which there are no approved therapies or where improved therapies are needed. These include post-stroke sensorimotor recovery, traumatic brain injury recovery, substance use disorder, or SUD, chronic cough, schizophrenia and mood related disorders.